NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 28, 2016--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products, today announced the appointment of Jack Crowley as
the Company’s Chief Financial Officer, effective immediately. Mr.
Crowley previously served as the Company’s interim Chief Financial
Officer since December 2015.
As Chief Financial Officer, Mr. Crowley will lead the Company’s Finance
function, including financial and operational reporting, planning and
analysis, together with the investor relations and information
technology functions. He will continue to report directly to Mary Anne
Heino, President and Chief Executive Officer.
Ms. Heino commented, “I am very pleased to announce Jack as our
permanent CFO. Jack is a focused, results-driven individual that has
consistently demonstrated his financial expertise and valuable
leadership across all aspects of our organization, not only during his
time as interim CFO but throughout his tenure with the Company. Together
with our management team and Board of Directors, I look forward to
continue working with Jack to further advance our business, drive
forward our strategic priorities and demonstrate our value proposition
to the investment community.”
Mr. Crowley, age 52, brings to the role more than 28 years of financial
management and accounting experience. He has steadily advanced to assume
broader executive leadership roles since joining the Company in
September 2010 as Director of Accounting. He was promoted to Vice
President of Finance in April 2013, to Chief Accounting Officer in March
2015 and to interim Chief Financial Officer in December 2015.
Mr. Crowley commented, “I appreciate the support of Mary Anne, the
executive team and our Board of Directors, and I am excited about the
opportunity to play a key role in our strategic growth as we continue to
provide essential diagnostic imaging products to help improve patient
care.”
Prior to joining Lantheus, Mr. Crowley served in the roles of Assistant
Corporate Controller, and prior to that, Director of Finance at Biogen
Idec. Mr. Crowley also previously served as Director of Accounting at
Fisher Scientific International. Prior to Fisher, Mr. Crowley was a
Senior Audit Manager in the Technology practice of
PriceWaterhouseCoopers.
Mr. Crowley holds a Master of Business Administration from the
University of Massachusetts and a Bachelor of Science in Business
Administration from Westfield State University, and is a Certified
Public Accountant.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc., which is a global leader in the development, manufacture
and commercialization of innovative diagnostic imaging agents and
products. LMI provides a broad portfolio of products, which are
primarily used for the diagnosis of cardiovascular diseases. LMI’s key
products include the echocardiography contrast agent DEFINITY®
Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. LMI is
headquartered in North Billerica, Massachusetts with offices in Puerto
Rico, Canada and Australia. For more information, visit www.lantheus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005356/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508
